Regulation of Cell Apoptosis and Proliferation in Pancreatic Cancer Through PI3K/Akt Pathway Via Polo-like Kinase 1

Overview

Journal Oncol Rep

Specialty Oncology

Date 2016 May 26

PMID 27220401

Citations 28

Authors

Yonghuan Mao

Ling Xi

Quan Li

Zeling Cai

Yimei Lai

Xinhua Zhang

Chunzhao Yu

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer has a poor prognosis. It is reported that the PI3K/Akt pathway is activated in many cancers, and inhibition of the PI3K/Akt pathway can induce cell apoptosis in most cancers. Polo-like kinase 1 (Plk1) is also overexpressed in most malignancies, and it controls multiple aspects of mitosis and apoptosis. Previous studies identified that PI3K/Akt-dependent phosphorylation of Plk1-Ser99 is required for metaphase-anaphase transition. In this study, we aimed to investigate the molecular mechanism of PI3K/Akt pathway regulating cell proliferation and apoptosis in pancreatic cancer cell lines (AsPC-1, BxPC-3, PANC-1). Immunohistochemistry (IHC) was used to assess Akt levels in human pancreatic tissues and pancreatic cancer tissues. MTT assay was used to detect cell proliferation. The mRNA was quantified by quantitative reverse transcription-PCR. Western blot analysis was used to detect the protein levels of p-Akt, Akt, Plk1, BAX, Bcl-2, XIAP, cleaved caspase-3 and caspase-3. Recombinant adenovirus vector containing Plk1-shRNA was constructed to inhibit Plk1 expression. Cell apoptosis was detected by flow cytometry and the apoptosis of tumor xenograft was assessed by TUNEL assay. The study showed that inhibition of PI3K/Akt pathway can induce cell apoptosis and reduce cell proliferation by downregulating Plk1 in vitro and in vivo. Additionally, Plk1 inhibition can lead to cancer cell apoptosis through inactivating XIAP, activating caspase-3, upregulating BAX and downregulating Bcl-2. Therefore, this study provided the molecular mechanism of PI3K/Akt pathway and Plk1 in the pancreatic cancer cell proliferation and apoptosis, which may benefit for the therapy of pancreatic cancer.

Citing Articles

Current understanding of PEAK family members in regulation of cellular signaling pathways and cancer therapy.

Alavi M, Roudi R, DAngelo A, Sobhani N, Safari F Mol Cell Biochem. 2025; .

PMID: 39922936 DOI: 10.1007/s11010-025-05219-w.

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.

Cheng K, Zhou Z, Chen Q, Chen Z, Cai Y, Cai H Sci Rep. 2024; 14(1):8389.

PMID: 38600093 PMC: 11006845. DOI: 10.1038/s41598-024-57417-z.

Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.

Yousef E, El-Mesery M, Habeeb M, Eissa L Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):4883-4894.

PMID: 38165424 DOI: 10.1007/s00210-023-02894-8.

CCNI2 promotes pancreatic cancer through PI3K/AKT signaling pathway.

Hu B, Zhang W, Zhang C, Li C, Zhang N, Pan K Biomol Biomed. 2023; 24(2):323-336.

PMID: 37540586 PMC: 10950348. DOI: 10.17305/bb.2023.9337.

Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: A systematic review and meta-analysis.

Wang M, Li Z, Chen L, Wang N, Hu J, Du J Front Oncol. 2022; 12:917366.

PMID: 36457496 PMC: 9705981. DOI: 10.3389/fonc.2022.917366.

References

Arlt A, Muerkoster S, Schafer H . Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2010; 332(2):346-58. DOI: 10.1016/j.canlet.2010.10.015. View

Edling C, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H . Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res. 2010; 16(20):4928-37. DOI: 10.1158/1078-0432.CCR-10-1210. View

Costello E, Greenhalf W, Neoptolemos J . New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012; 9(8):435-44. DOI: 10.1038/nrgastro.2012.119. View

Ng SSW , Tsao M, Chow S, Hedley D . Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000; 60(19):5451-5. View

Christensen M, Jansen E, Sanchez W, Waterhouse N . Flow cytometry based assays for the measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release. Methods. 2013; 61(2):138-45. DOI: 10.1016/j.ymeth.2013.03.020. View

Bondar V, Sweeney-Gotsch B, Andreeff M, Mills G, McConkey D . Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002; 1(12):989-97. View

Ng S, Tsao M, Nicklee T, Hedley D . Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001; 7(10):3269-75. View

Elghazi L, Weiss A, Barker D, Callaghan J, Staloch L, Sandgren E . Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology. 2009; 136(3):1091-103. PMC: 2739876. DOI: 10.1053/j.gastro.2008.11.043. View

Dan H, Sun M, Kaneko S, Feldman R, Nicosia S, Wang H . Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem. 2003; 279(7):5405-12. DOI: 10.1074/jbc.M312044200. View

10.

Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H . Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A. 1994; 91(5):1736-40. PMC: 43238. DOI: 10.1073/pnas.91.5.1736. View

11.

Lo A, Woo T, Wong R, Wong D . Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica. 2011; 226 Suppl 1:10-7. DOI: 10.1159/000328206. View

12.

Lowe S, Lin A . Apoptosis in cancer. Carcinogenesis. 2000; 21(3):485-95. DOI: 10.1093/carcin/21.3.485. View

13.

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V . K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One. 2012; 7(8):e44146. PMC: 3432074. DOI: 10.1371/journal.pone.0044146. View

14.

Goldar S, Shekari Khaniani M, Mansoori Derakhshan S, Baradaran B . Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015; 16(6):2129-44. DOI: 10.7314/apjcp.2015.16.6.2129. View

15.

Michl P, Downward J . Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol. 2005; 43(10):1133-9. DOI: 10.1055/s-2005-858638. View

16.

Schlieman M, Fahy B, Ramsamooj R, Beckett L, Bold R . Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer. 2003; 89(11):2110-5. PMC: 2376856. DOI: 10.1038/sj.bjc.6601396. View

17.

Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P . Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology. 2005; 5(2-3):259-65. DOI: 10.1159/000085280. View

18.

Weichert W, Roske A, Gekeler V, Beckers T, Ebert M, Pross M . Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008; 9(2):139-48. DOI: 10.1016/S1470-2045(08)70004-4. View

19.

Strebhardt K . Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010; 9(8):643-60. DOI: 10.1038/nrd3184. View

20.

Yu C, Zhang X, Sun G, Guo X, Li H, You Y . RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med. 2008; 12(6A):2334-49. PMC: 4514112. DOI: 10.1111/j.1582-4934.2008.00257.x. View